CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial

The New York Times | June 16, 2021, 5:25 p.m. | Original

A preliminary analysis showed that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.

Israelis Wonder When or Whether Netanyahu Will Exit Official Residence Biden and Putin Express Desire for Better Relations at Summit Shaped by Disputes